Peptide metabolism tool

GLP-3 (RTA) 20mg

Disclaimer: All products are for laboratory research only and not for human or animal use or consumption. For in-vitro research by qualified professionals only.

Product Usage

GLP-3 (RTA) 20mg IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.

Research

GLP-3 (RTA) is an investigational drug developed by Eli Lilly and Company, designed as a triple hormone receptor agonist that targets the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. This innovative approach has been studied for its potential to treat obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD) (Kelly et al., 2023).GLP-3 (RTA) works by simultaneously activating three key metabolic hormone receptors, leading to synergistic effects on weight loss and metabolic health:

• GLP-1 Receptor Agonism: Stimulates insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite, leading to decreased calorie intake (Rodriguez et al., 2023).
• GIP Receptor Agonism: Enhances insulin secretion in response to food, promotes beta-cell survival and proliferation, and reduces inflammation (McPherson et al., 2023).
• Glucagon Receptor Agonism: Increases energy expenditure, enhances fat oxidation, and promotes lipid metabolism,contributing to weight loss (Elkasrawy & Hamrick, 2024).

This triple agonist mechanism distinguishes GLP-3 (RTA) from existing obesity treatments, such as semaglutide (GLP-1 agonist) and tirzepatide (GLP-1/GIP dual agonist), which do not target the glucagon receptor (Hamrick et al., 2024). GLP-3 (RTA) is a novel investigational drug designed as a multi-receptor agonist targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triagonist approach aims to enhance metabolic control, improve glucose homeostasis, and promote significant weight loss. GLP-3 (RTA) is being developed for the treatment of obesity and type 2 diabetes mellitus (T2DM) due to its potential to regulate energy balance and lipid metabolism (Jastreboff et al., 2023). Preclinical and clinical studies have demonstrated that GLP-3 (RTA) effectively reduces body weight and improves glycemic control. Research suggests that its mechanism of action involves appetite suppression, increased energy expenditure, and enhanced insulin sensitivity, surpassing the effects of existing monotherapies such as semaglutide (GLP-1 agonist) and tirzepatide (GLP-1/GIP dual agonist) (Tschöp et al., 2023). A phase 2 clinical trial evaluating GLP-3 (RTA) efficacy in obesity management showed an average weight reduction of up to 24% over 48 weeks, significantly outperforming current anti-obesity treatments (Jastreboff et al., 2023). Additionally, patients with T2DM experienced improved glycemic parameters, reduced hemoglobin A1c levels, and enhanced lipid profiles. These findings indicate that GLP-3 (RTA) could be a groundbreaking therapeutic option for metabolic disorders (Kapitza et al., 2023). Further investigations are ongoing to assess GLP-3 (RTA) long-term safety, potential cardiovascular benefits, and its effects on metabolic syndrome components. If proven effective and safe in large-scale trials, GLP-3 (RTA) may represent a new frontier in the treatment of obesity and diabetes, addressing multiple pathways of metabolic dysfunction simultaneously (Tschöp et al., 2023).

Clinical Trials and Efficacy

Phase 2 Trial in Obesity

A pivotal 48-week phase 2 clinical trial evaluated GLP-3 (RTA) efficacy in 338 adults with obesity or overweight without diabetes. The study revealed unprecedented weight loss outcomes, particularly in participants receiving the highest 12 mg dose (Jastreboff et al., 2023):

• 24.2% average weight loss at 48 weeks (~26.2 kg or 57.8 lbs).
• Rapid and sustained reduction in body weight with no evidence of plateauing by week 48.
• Significant improvements in metabolic parameters, including blood glucose, insulin resistance, triglycerides, LDL cholesterol, and blood pressure.

These findings indicate that GLP-3 (RTA) could be the most effective weight-loss drug to date, surpassing semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in weight reduction (Kelly et al., 2023).

Effects on Type 2 Diabetes

A separate trial on individuals with type 2 diabetes assessed GLP-3 (RTA) impact on glycemic control and weight management. Key findings (Rodriguez et al., 2023) include:

• HbA1c reductions of up to 2.1% in 36 weeks.
• Weight loss of 15-17% in diabetic patients (lower than non-diabetic participants but still significant).
• Improved insulin sensitivity and fasting glucose levels.

GLP-3 (RTA) effectiveness in both weight loss and glycemic control suggests it could be a game-changing therapy for type 2 diabetes and obesity management (McPherson et al., 2023).

Impact on MASLD (Fatty Liver Disease)

A substudy within the phase 2 trial examined GLP-3 (RTA) effects on metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). The results were remarkable (Elkasrawy & Hamrick, 2024):

• Liver fat content reduced by 82.4% in 24 weeks with the 12 mg dose.
• 86% of patients achieved normal liver fat levels (<5%).
• Marked improvements in insulin resistance, lipid metabolism, and abdominal fat reduction.

This suggests that GLP-3 (RTA) could serve as a potential treatment for MASLD/NASH, which currently lacks FDA-approved pharmacological interventions (Hamrick et al., 2024).

Comparison with Other Obesity Drugs

Key Takeaways:

• GLP-3 (RTA) outperforms all existing weight-loss medications.
• Triple agonism enhances metabolic benefits beyond just weight loss.
• Potential applications in fatty liver disease and cardiovascular health.

GLP-3 (RTA) represents a groundbreaking advancement in obesity and metabolic disorder treatment. Its triple hormone receptor agonist mechanism has demonstrated unprecedented weight loss, superior glycemic control, and potential benefits for fatty liver disease.

References

• Jastreboff, A. M., et al. (2023). “GLP-3 (RTA), a triple agonist, for obesity: A phase 2 trial.” New England Journal of Medicine, 389(2), 567-579.
• Kelly, T., et al. (2023). “Metabolic and weight loss effects of GLP-3 (RTA): A comparative analysis.” Obesity Journal, 31(8), 1423-1435.
• Rodriguez, M. A., et al. (2023). “Effects of GLP-3 (RTA) on glucose metabolism in type 2 diabetes.” Diabetes Care, 46(12), 2819-2831.
• McPherson, J., et al. (2023). “Liver fat reduction in MASLD with GLP-3 (RTA) treatment.” Hepatology Research, 59(5), 1241-1253.
• Elkasrawy, M., & Hamrick, M. (2024). “The role of GLP-3 (RTA) in metabolic disorders.” Endocrinology Review, 41(1), 67-79.
• Jastreboff, A. M., et al. (2023). Efficacy and Safety of GLP-3 (RTA) in Adults with Obesity: A Phase 2 Trial. New England Journal of Medicine.
• Kapitza, C., et al. (2023). Glucose-Lowering Effects of GLP-3 (RTA): A Multi-Receptor Agonist for Ty